FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Landau Jeffrey B				2. Issuer Name and Ticker or Trading Symbol CytomX Therapeutics, Inc. [CTMX]							(Che	elationship of ck all applica Director Officer (able)	J Perso	on(s) to Issu 10% Ov Other (s	vner		
(Last) (First) (Middle) C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400				3. Date of Earliest Transaction (Month/Day/Year) 08/10/2022								below)	hief Busi	ness (below)` Officer			
(Street) SOUTH S FRANCIS	(· A)4080	-	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. In Line								
(City)	(Sta		Zip)		<u> </u>													
1. Title of Security (Instr. 3) 2. Tr Date (Mor			2. Transa Date (Month/E	·		3. Transac Code (I 8)	ction nstr.	(D)		d (A) or r. 3, 4 and 5 Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
											onvertib			owned				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		ate, T	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				c	ode \	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	ion(s)		
Stock Option (Right to Buy)	\$1.59	08/10/2022			A		135,000		(1)		08/09/2032	Common Stock	135,000	\$0.00	135,00	00	D	
Performance Stock Units (PSUs)	(2)	08/10/2022			A		22,500		(2)		(2)	Common Stock	22,500	\$0.00	22,50	00	D	

Explanation of Responses:

- 1. 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
- 2. Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.

/s/ Lloyd Rowland, as Attorneyin-Fact for Jeffrey B Landau

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.